Enzo Biochem INC: insider trades · United States · SEC (Form 4)

About Enzo Biochem INC

Enzo Biochem Inc. is a U.S.-based life sciences company with a long operating history and a niche position in research tools and diagnostics. It began operations in August 1976 and is headquartered in Farmingdale, New York, United States. From a market perspective, the company was long associated with the NYSE, but in 2025 it voluntarily delisted from the NYSE and moved its common stock trading to the OTCQX market under the symbol ENZB. For investors, that change is important because it reflects both the company’s small-cap profile and the evolution of its capital-markets access. ([ir.enzo.com](https://ir.enzo.com/company-information/faq?utm_source=openai)) Today, Enzo’s core business is conducted through Enzo Life Sciences. The company focuses on labeling and detection technologies spanning DNA-based applications through whole-cell analysis. Its portfolio includes antibodies, genomic probes, assays, biochemicals, and proteins, which are used in translational research, drug discovery, drug development, cell biology, genomics, immunohistochemistry, and related scientific workflows. Enzo also highlights a sizeable intellectual-property base and a large installed scientific reputation, with more than 500 patents and a long record of peer-reviewed citations supporting its product franchise. ([enzo.com](https://www.enzo.com/about-enzo/?utm_source=openai)) In competitive terms, Enzo operates in a specialized segment of the global life-science tools market. It competes with larger diversified suppliers, but its differentiation comes from a focused catalog, internally supported manufacturing and validation, and a product set that is tailored to researchers, biotech companies, pharma customers, and diagnostic users. The company describes its Long Island campus as a hub for research and development, manufacturing, customer service, and warehouse operations, while also serving a global market through distribution channels and product sales. ([enzo.com](https://www.enzo.com/about-enzo/locations/?utm_source=openai)) Recent headlines have been shaped by corporate simplification and risk management. In March 2025, Enzo announced its intent to delist from the NYSE; the last day of NYSE trading was April 17, 2025, and OTCQX trading began on April 21, 2025. In parallel, the company disclosed progress on a class-wide settlement related to the April 2023 cyber incident, with court approval granted in June 2025. On the operating side, management emphasized new product launches, stating that approximately 100 products were launched during the third quarter of fiscal 2025, while also noting continued headwinds in life-science tools, including weaker government grant activity, reduced R&D spending, and tariff-related uncertainty. ([ir.enzo.com](https://ir.enzo.com/news-events/press-releases/detail/342/enzo-biochem-reports-third-quarter-fiscal-year-2025-results?utm_source=openai)) Overall, Enzo Biochem is best viewed as a specialized U.S. life-sciences company with a defensible technology niche, a global product footprint, and a recent history of strategic and listing-related changes that are material for equity investors. ([ir.enzo.com](https://ir.enzo.com/news-events/press-releases/detail/342/enzo-biochem-reports-third-quarter-fiscal-year-2025-results?utm_source=openai))